Pharmacy Focus: Oncology Edition- Benefits of Subcutaneous Amivantamab for Lung Cancer Treatment

The PALOMA-3 trial showed subcutaneous amivantamab was better than IV among lung cancer patients.

This month, we spoke with Natasha B. Leighl, BSc, MMSc, MD, Medical Oncologist at the Princess Margaret Cancer Centre in Toronto, Canada. Leighl discussed the PALOMA-3 trial results, shared at the American Society of Clinical Oncology 2024 Conference. Leighl noted that the trial compared subcutaneous and intravenous administration of amivantamab for lung cancer.